论文部分内容阅读
报告８４例慢性丙型肝炎（ＣＨＣ）患者，通过临床、血清学、肝组织学、分子生物学和免疫组织化学等方法，观察应用重组α－干扰素加传统护肝治疗的效果，疗程２４周，并与单用传统护肝治疗的对照组治疗前后各项指标变化比较。疗程结束时结果显示：治疗组６４例中，血清ＡＬＴ复常率为７０．３％，ＨＣＶ－ＲＮＡ阴转率为６７．２％，肝组织学好转率为６５．６％，肝组织内ＨＣＶ－ＲＮＡ阴转率为５１．５％，肝组织内ＨＣＶ－Ａｇ抗原的免疫组化检出率从治疗前的１５．６％减至治疗后的６．３％，分别显著高于对照组（Ｐ＜０．０５）。疗程结束后随访３～６个月，测定ＨＣＶ－ＲＮＡ并动态观察血清ＡＬＴ的变化，部分病人有复发，但治疗组ＡＬＴ复常率及ＨＣＶ－ＲＮＡ阴转率仍达７０．０％。
Reported 84 cases of chronic hepatitis C (CHC) patients, clinical, serological, liver histology, molecular biology and immunohistochemistry and other methods to observe the effect of recombinant interferon plus traditional liver protection treatment for 24 weeks , And compared with the control group before and after treatment with traditional liver protection alone. At the end of the course of treatment, the results showed that the normal ALT rate was 70.3%, the HCV-RNA negative rate was 67.2%, the liver histological improvement rate was 65.6% -RNA negative rate was 51.5%, and the detection rate of HCV-Ag antigen in liver tissue was reduced from 15.6% before treatment to 6.3% after treatment, which were significantly higher than that of the control group P <0.05). The patients were followed up for 3 to 6 months after the course of treatment. The changes of serum ALT were measured and some patients had recurrence. However, the recovery rate of ALT and HCV-RNA negative conversion rate still reached 70.0% in the treatment group.